Immunodominant allergens as molecular targets for allergen immunotherapy

While there has been tremendous progress in allergen molecular biology, knowledge of the epitopes recognized by IgE antibodies is in its infancy. The production of IgE monoclonal antibodies from symptomatic allergic patients has enabled structures of allergen/IgE complexes to be solved and has defined immunodominant epitopes on indoor allergens and foods. High resolution structures of IgE epitopes on Der p 2, Can f 1, Fel d 7, Fel d 1, Ara h 2, Ara h 6 and Bet v 1 have been determined. Mutations of these epitopes show reduced IgE binding in vitro and confer protection in a murine model of anaphylaxis, making them candidate hypoallergens for potential therapeutic use. Allergens and IgE antibodies are important tools for next generation diagnostics using basophil or mast cell activation tests. Immunodominant allergens from diverse sources are molecular targets for novel therapeutics using virus-like particle vaccines or plant-based enveloped particles. Allergen-specific precision biologics are being engineered to target immunodominant allergens using high affinity IgG antibodies to block IgE epitopes and to downregulate signal transduction through IgE pathways. Promising data from clinical trials suggests that targeting one or more immunodominant allergens provides symptomatic relief from challenge with allergen extracts. Innovative strategies targeting, in effect, the active pharmaceutical ingredients of conventional allergen extracts are poised to develop new therapeutic options for treatment of patients with allergic diseases.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.2012996
Primary Topic
Allergic Rhinitis and Sensitization
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immunodominant allergens as molecular targets for allergen immunotherapy

Martin D. Chapman, Scott Alan Smith, M. Chruszcz, Anna Pomés et al.
Frontiers in Immunology
Allergic Rhinitis and Sensitization
article

Immunodominant allergens as molecular targets for allergen immunotherapy

Martin D. Chapman, Scott Alan Smith, M. Chruszcz, Anna Pomés, Kriti Khatri, Ben W. Spiller
article en

Abstract

While there has been tremendous progress in allergen molecular biology, knowledge of the epitopes recognized by IgE antibodies is in its infancy. The production of IgE monoclonal antibodies from symptomatic allergic patients has enabled structures of allergen/IgE complexes to be solved and has defined immunodominant epitopes on indoor allergens and foods. High resolution structures of IgE epitopes on Der p 2, Can f 1, Fel d 7, Fel d 1, Ara h 2, Ara h 6 and Bet v 1 have been determined. Mutations of these epitopes show reduced IgE binding in vitro and confer protection in a murine model of anaphylaxis, making them candidate hypoallergens for potential therapeutic use. Allergens and IgE antibodies are important tools for next generation diagnostics using basophil or mast cell activation tests. Immunodominant allergens from diverse sources are molecular targets for novel therapeutics using virus-like particle vaccines or plant-based enveloped particles. Allergen-specific precision biologics are being engineered to target immunodominant allergens using high affinity IgG antibodies to block IgE epitopes and to downregulate signal transduction through IgE pathways. Promising data from clinical trials suggests that targeting one or more immunodominant allergens provides symptomatic relief from challenge with allergen extracts. Innovative strategies targeting, in effect, the active pharmaceutical ingredients of conventional allergen extracts are poised to develop new therapeutic options for treatment of patients with allergic diseases.

Frontiers in ImmunologyVol. 17
Vanderbilt University (US), University of Virginia (US), Michigan State University (US)
National Institutes of Health, National Institute of Allergy and Infectious Diseases
Good health and well-being
Allergic Rhinitis and Sensitization
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon